An FDA inspector recommended a plant in Zhejiang, China, be sanctioned for failing to investigate impurity spikes in its drugs.

“the FDA does these pre announced inspections overseas and their inspector went to one of these plants in China it's a camera it's Zhejiang who a high plant and the investigator found that the company was not investigating impurity spikes in its own drugs as required so the inspector recommended that this plant be sanctioned as official action indicated like the most serious which would have forced them to take action back in Maryland FDA officials said it's okay voluntary action indicated not such a big deal”